RxDoctor Payments Data

Mrugesh Soni, MD

Interventional Cardiology · Newport News, VANPI 1508028937

Payments from drug & device makers

$2,202in general payments, 2019–2025

Across 126 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$333
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$278
  • E.r. Squibb & Sons, L.L.C.$259
  • AstraZeneca$257
  • Amgen$227
  • Philips North America LLC$193
  • plus $654 from 11 others

What the payments were for

  • Food & beverage$2,197100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,202 in reported general payments places this provider in the 30th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$496,270
Medicare patients
1,170
Services billed
5,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban434$417,643
XareltoRivaroxaban166$178,777
MultaqDronedarone Hcl38$59,220
EntrestoSacubitril/Valsartan38$37,807
BrilintaTicagrelor35$29,395
Ranolazine ErRanolazine81$6,975
Metoprolol Succinate439$5,254
Isosorbide Dinitrate118$3,553
Flecainide Acetate50$2,503
Metoprolol Tartrate453$2,291
Bumetanide75$1,444
Atorvastatin Calcium204$1,374
Diltiazem 24hr Er (Cd)Diltiazem Hcl62$1,269
Labetalol Hcl33$1,167
Amiodarone Hcl47$1,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$417,643434 claims
Johnson & JohnsonXarelto$333$178,777166 claims
Sanofi-aventis U.S. LLCMultaq$105$59,22038 claims
NovartisEntresto$33$37,80738 claims
AstraZenecaBrilinta$257$29,39535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →